New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 5, 2014
06:35 EDTREGNRegeneron reports Q2 EPS $2.47, consensus $2.30
Reports Q2 revenue $665.7M, consensus $647.59M. Reports Q2 EYLEA net product sales in the United States were $415M.
News For REGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 20, 2015
09:20 EDTREGNLeerink biotech analyst holds an analyst/industry conference call
Subscribe for More Information
April 10, 2015
07:17 EDTREGNExpert very bullish on outlook for Regeneron Eylea, says RBC Capital
RBC Capital reports that a retina expert with whom it spoke was "very bullish" on the outlook for Regeneron's Eylea, not just in DME but also in wet AMD. The firm says the expert's positive outlook was sparked by recently presented Protocol T data. RBC continues to believe that Eylea could beat guidance this year, while Phase III programs could boost the stock. RBC keeps a $490 price target and Outperform rating on the shares.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use